India's largest platform for AI & Analytics leaders & professionals

Sign in

India's largest platform for AI & Analytics leaders & professionals

3AI Digital Library

Cloud4C and Google Cloud to build CoE for SAP and Anthos

3AI February 1, 2021

The partnership aims to enable enterprises to accelerate their digital transformation journey on the cloud.

Picture from freepik.com

    3AI Trending Articles

  • Global Captive Centers – The true enablers of Collaboration (Part-1)

    Featured Article: Author: Vinodh Ramachandran, Neiman Marcus Group Through my experience working for large retail GCCs I. have observed that most retailers, in addition to having a central data & analytics team (typically within tech rolling up to the CIO), also have analytics teams within the businesses running independently and managing all their data, reporting […]

  • India’s answer to Dropbox and Google Drive: NITI Aayog’s DigiBoxx

    Homegrown data storage and management platform DigiBoxx has been launched by NITI Aayog and it will provide affordable services to both regular users as well as businesses. India now has its own cloud storage platform, DigiBoxx. A potential alternative to Google Drive, Dropbox, and Microsoft OneDrive, the indigenous cloud service is seen as a step that furthers the initiative […]

  • Revenue Growth Management in the New E-Commerce-led Phygital World

    Author: Imran Saeed, Vice President and Global Head CPG, Course5 Intelligence (LinkedIn – linkedin.com/in/imran-saeed-608a3b1) ‘Phygital’ is a portmanteau of ‘physical’ and ‘digital’ and symbolizes the seamless relationship between the two channels. It takes the best elements from both and merges them to create an entirely new customer retail experience. Though this does bring in a […]

  • AI in Drug Discovery

    Featured Article: Author: Vijay Morampudi, Director & Head of AI, Wavelabs Technologies Drug discovery takes 12-15 years and a median investment of nearly $1 billion to bring a new drug to market. While the true cost of research and development may be as high as $2.5 billion per marketed therapy, when factoring in abandoned trials and […]